Company Overview and News

 
Huhtamaki PPL Limited - Trading Window

2018-10-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Huhtamaki PPL Limited - Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Huhtamaki PPL Limited - Financial Result Updates

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Huhtamaki PPL Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Huhtamaki PPL Limited - Change in Director(s)

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Huhtamaki PPL Limited - Updates

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Huhtamaki PPL Limited - Trading Window

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Company news: Huhtamaki PPL

2018-06-04 thehindubusinessline
Huhtamaki PPL has informed the exchanges that there was a fire accident at its factory at TTC Industrial Estate, Processing Zone, Mahape, Navi Mumbai, on Saturday. The fire, which broke out in an adjoining factory, spread to its factory, but was brought under control by the Fire Brigade, it said. The company is in the process of ascertaining the actual loss caused by the fire and has informed the insurance company.
PAPERPROD PNJZY 532461 PNB 509820

33
Closing Bell: Sensex down over 200 pts, Nifty ends below 10,650; banks drag

2018-06-04 moneycontrol
RBI Policy Expectations: India Ratings believes the Reserve Bank of India’s Monetary Policy Committee (MPC) will keep the policy rate unchanged in its upcoming review.
500325 500820 RELIANCE 532714 532978 BHRQY ASIANPAINT 532343 500470 PAPERPROD RIGD HDFCBANK 500570 BHARTIARTL KEC TATAMOTORS 509488 509820 RLNIY TVSMOTOR GRAPHITE KMBKY IBN 532454 ICICIBANK BAJAJFINSV TTST TATASTEEL TATLY HDB 532174 500180 KOTAKBANK 534809 500247 PCJEWELLER TTM

25
Market Live: Nifty extends losses, Sensex falls 200 pts; Nifty Bank sheds 400 pts

2018-06-04 moneycontrol
DHFL raises nearly Rs 11,000 crore: Housing financier DHFL has raised over Rs 10,944 crore through public issue of bonds which had open for subscription in May.
500325 500820 RELIANCE 532978 BHRQY ASIANPAINT CADILAHC 532321 PAPERPROD RIGD HDFCBANK 500570 BHARTIARTL TATAMOTORS 509820 RLNIY KMBKY IBN CDLYY 532454 ICICIBANK BAJAJFINSV HDB 532174 500180 KOTAKBANK 500247 TTM

32
Market Live: Sensex slips 100 pts, Nifty Bank dips 250 pts; advance:decline ratio 3:1

2018-06-04 moneycontrol
Earnings in the final quarter of FY18 were marked by sustained traction and the prospect of capex in consumption-facing businesses, infrastructure spending by the government, and strong growth in commodity-driven companies and digital-ready information technology players.
500325 RELIANCE 533278 CADILAHC 532321 PAPERPROD 532187 ANANTRAJ RIGD 526521 HDFCBANK HEROMOTOCO BJJQY SANGHIIND 500570 TATAMOTORS CLNDY 509820 RLNIY 500034 515055 INDUSINDBK IBN CANFINHOME 511196 CDLYY 500182 ICICIBANK BAJFINANCE HDB 532174 500180 HRTQY COALINDIA TTM

 
Huhtamaki PPL Limited - Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Huhtamaki PPL Limited - Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

 
Huhtamaki PPL Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PAPERPROD 509820

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...